Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -65.87% is 26% above its 5-year average of -89.00%, near the high end of its 5-year range (-155.91%–-55.19%).
40.52% above its 12-month average of -110.74%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -20.03%.
RETURN ON ASSETS (ROA)
-65.87%
RETURN ON ASSETS (ROA) AVG TTM
-110.74%
RETURN ON ASSETS (ROA) AVG 3Y
-99.78%
RETURN ON ASSETS (ROA) AVG 5Y
-89.00%
RETURN ON ASSETS (ROA) AVG 10Y
-97.76%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
+40.52%
CURRENT VS 3Y AVG
+33.98%
CURRENT VS 5Y AVG
+25.99%
CURRENT VS 10Y AVG
+32.62%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-104.31%
vs the sector median at left
Ocugen, Inc.
Market Cap
$356.88M
Return on Assets (ROA)
-65.87%
TTM Avg
-110.74%
3Y Avg
-99.78%
5Y Avg
-89.00%
Market Cap
$357.44M
Return on Assets (ROA)
6.92%
TTM Avg
7.42%
3Y Avg
10.30%
5Y Avg
25.30%
Market Cap
$356.41M
Return on Assets (ROA)
-24.64%
TTM Avg
-45.98%
3Y Avg
-40.55%
5Y Avg
-44.33%
Market Cap
$356.32M
Return on Assets (ROA)
7.10%
TTM Avg
6.66%
3Y Avg
6.31%
5Y Avg
10.17%
Market Cap
$357.53M
Return on Assets (ROA)
-49.80%
TTM Avg
-56.29%
3Y Avg
-75.47%
5Y Avg
-75.47%
Market Cap
$357.30M
Return on Assets (ROA)
-21.30%
TTM Avg
-29.99%
3Y Avg
-30.23%
5Y Avg
-24.37%
Market Cap
$355.71M
Return on Assets (ROA)
-4.29%
TTM Avg
-7.44%
3Y Avg
-40.66%
5Y Avg
-49.61%
Market Cap
$353.90M
Return on Assets (ROA)
-51.02%
TTM Avg
-63.00%
3Y Avg
-53.19%
5Y Avg
-73.16%
Market Cap
$363.51M
Return on Assets (ROA)
-115.75%
TTM Avg
-127.38%
3Y Avg
-59.19%
5Y Avg
-98.90%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocugen, Inc. (OCGN) | $356.88M | -65.87% | -110.74% | -99.78% | -89.00% |
| Embecta Corp. (EMBC)vs › | $357.44M | 6.92% | 7.42% | 10.30% | 25.30% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $356.41M | -24.64% | -45.98% | -40.55% | -44.33% |
| Viemed Healthcare, Inc. (VMD)vs › | $356.32M | 7.10% | 6.66% | 6.31% | 10.17% |
| Turn Therapeutics Inc. (TTRX)vs › | $357.53M | -49.80% | -56.29% | -75.47% | -75.47% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $357.30M | -21.30% | -29.99% | -30.23% | -24.37% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $355.71M | -4.29% | -7.44% | -40.66% | -49.61% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $353.90M | -51.02% | -63.00% | -53.19% | -73.16% |
| Opus Genetics, Inc. (IRD)vs › | $363.51M | -115.75% | -127.38% | -59.19% | -98.90% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $349.81M | -28.27% | -117.81% | -109.90% | -91.03% |
ROA
-65.9%
ROE
N/A
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -155.91% |
| 2024-12-31 | -65.57% |
| 2023-12-31 | -97.72% |
| 2022-12-31 | -79.91% |
| 2021-12-31 | -55.19% |
| 2020-12-31 | -79.71% |
| 2019-12-31 | -120.44% |
| 2018-12-31 | -49.59% |
| 2017-12-31 | -239.37% |
| 2016-12-31 | -44.92% |
| 2015-12-31 | -87.05% |
| 2014-12-31 | -34.80% |
| 2013-12-31 | -173.78% |
| 2012-12-31 | -80.47% |
